Jeff Baxter
Chief Executive Officer bij VBI VACCINES INC.
Vermogen: 12 225 $ op 31-03-2024
Profiel
Jeffrey R. Baxter is President, Chief Executive Officer & Bestuurder bij VBI Vaccines, Inc., een Onafhankelijk Niet-Uitvoerend Bestuurder bij Chromadex Corp., een President, Chief Executive Officer & Bestuurder bij VBI Vaccines (Delaware), Inc. en een President, Chief Executive Officer & Bestuurder bij Variation Biotechnologies (US), Inc. Hij is lid van de Raad van Bestuur van VBI Vaccines, Inc., Chromadex Corp., VBI Vaccines (Delaware), Inc. en Variation Biotechnologies (US), Inc. De heer Baxter was voorheen werkzaam als SVP-Finance, Operations, Research & Development bij GlaxoSmithKline Plc, als Principal bij British American Tobacco plc, als Managing Partner bij The Column Group LLC, en als Principal bij Unilever Plc. Hij behaalde zijn bachelordiploma aan de Thames Valley University.
Bekende belangen in openbare bedrijven
Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
---|---|---|---|---|
VBI VACCINES, INC.
0.09% | 27-07-2023 | 20 274 ( 0.09% ) | 12 225 $ | 31-03-2024 |
Actieve functies van Jeff Baxter
Bedrijven | Functie | Begin |
---|---|---|
VBI VACCINES INC. | Chief Executive Officer | 01-05-2016 |
Variation Biotechnologies (US), Inc.
Variation Biotechnologies (US), Inc. BiotechnologyHealth Technology Variation Biotechnologies (US), Inc. develops and manufactures vaccines for infectious diseases. It is dedicated to the innovative formulation, development and delivery of safe and effective vaccines that expand and enhance vaccine protection in both established and emerging markets. The company was founded by David E. Anderson and Adam Buckley in 2001 and is headquartered in Boston, MA. | Chief Executive Officer | 22-09-2009 |
VBI Vaccines (Delaware), Inc.
VBI Vaccines (Delaware), Inc. BiotechnologyHealth Technology Part of VBI Vaccines, Inc., VBI Vaccines (Delaware), Inc. develops biopharmaceuticals. Jeffrey R. Baxter has been the CEO of the American company since 2014. | Chief Executive Officer | 01-07-2014 |
Eerdere bekende functies van Jeff Baxter
Bedrijven | Functie | Einde |
---|---|---|
CHROMADEX CORPORATION | Director/Board Member | 04-04-2022 |
The Column Group LLC
The Column Group LLC Investment ManagersFinance The Column Group LLC is a venture capital firm founded in 2005 by Peter Svennilson. The firm is headquartered in San Francisco. | Chief Investment Officer | 28-02-2009 |
GSK PLC | Corporate Officer/Principal | 01-07-2006 |
UNILEVER PLC | Corporate Officer/Principal | - |
BRITISH AMERICAN TOBACCO P.L.C. | Corporate Officer/Principal | - |
Opleiding van Jeff Baxter
University of West London | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 5 |
---|---|
BRITISH AMERICAN TOBACCO P.L.C. | Consumer Non-Durables |
UNILEVER PLC | Consumer Non-Durables |
GSK PLC | Health Technology |
CHROMADEX CORPORATION | Health Technology |
VBI VACCINES INC. | Health Technology |
Bedrijven in privébezit | 3 |
---|---|
Variation Biotechnologies (US), Inc.
Variation Biotechnologies (US), Inc. BiotechnologyHealth Technology Variation Biotechnologies (US), Inc. develops and manufactures vaccines for infectious diseases. It is dedicated to the innovative formulation, development and delivery of safe and effective vaccines that expand and enhance vaccine protection in both established and emerging markets. The company was founded by David E. Anderson and Adam Buckley in 2001 and is headquartered in Boston, MA. | Health Technology |
The Column Group LLC
The Column Group LLC Investment ManagersFinance The Column Group LLC is a venture capital firm founded in 2005 by Peter Svennilson. The firm is headquartered in San Francisco. | Finance |
VBI Vaccines (Delaware), Inc.
VBI Vaccines (Delaware), Inc. BiotechnologyHealth Technology Part of VBI Vaccines, Inc., VBI Vaccines (Delaware), Inc. develops biopharmaceuticals. Jeffrey R. Baxter has been the CEO of the American company since 2014. | Health Technology |